Vol 4 Issue 11

Strategies for Scale-up & Scale-out

Dec 2018

Guest Editor:

Prof Nik Willoughby,

Editorial

Critical considerations for allogeneic cell therapy scale up

Sharon Grimster

18 December 2018

Editorial

Research Article

Scale-up of a perfusion-based dendritic cell generation process

Andrew Kozbial,

Hope Weinstein,

Shashi K Murthy,

Jennifer Rossi

18 December 2018

Research Article

Expert Insight

The long road to affordability: a cost of goods analysis for an autologous CAR-T process

Katy Spink,

Andrew Steinsapir

18 December 2018

Expert Insight

Back to the future: where are we taking lentiviral vector manufacturing?

Hanna P Lesch

18 December 2018

Expert Insight

Translating cell and gene therapies to the clinic

Hema Dave,

Devin Saunders,

Nan Zhang,

Patrick J Hanley

18 December 2018

Expert Insight

Innovator Insight

Commercial Lessons for Clinical Success

Simon Ellison,

Heidi Hagen,

Christophe Suchet

19 December 2018

Innovator Insight

Interview

Biopharma scale-up lessons to learn for cell & gene therapy

Nik Willoughby

8 January 2019

Interview

Towards commercial allogeneic cell therapy manufacturing

Maria Del Pilar Redondo

18 December 2018

Interview

Autologous T cell immunotherapy scale out manufacturing models – the biotech perspective

Nina Kotsopoulou

18 December 2018

Interview

Scale-Out and -Up Strategies

Oct 2017

Expert Insight

Scale-up of lentiviral vectors for gene therapy: advances and challenges

Alexandra McCarron,

Martin Donnelley,

David Parsons

16 November 2017

Expert Insight

Interview

Approaches and challenges for the manufacture and scale-out of autologous cell therapies

Richard Harrison

16 November 2017

Interview

Research Article

Methylcellulose as a scaffold in the culture of liver-organoids for the potential of treating acute liver failure

Anil Chandrashekran,

Valeria Iansante,

Anil Dhawan,

Tharindu Premachan-dra,

Chris Starling,

Sharon Lehec,

Emer Fitzpatrick,

Celine Filippi,

Maesha Deherago-da,

Ragai R Mitry et al.

18 December 2018

Research Article

Expert Insight

Management of ‘out of specification’ commercial autologous CAR-T cell products

Alexey Bersenev,

Sven Kili

17 December 2018

Expert Insight

Built to scale: strategic considerations to meet production demands in cell and gene therapy

Stephen Ward, COO at Cell and Gene Therapy Catapult

Ian Gaudet, Senior Director of Process Sciences at Miltenyi Biotec

Heather Embree, Director, Commercial Operations at Lentigen Technology Inc

9 January 2018

Webinar

Watch now

CELL & GENE THERAPY INSIGHTS

Nov 2018. Vol 4 Issue 11

FEATURING

Spotlight

Strategies for Scale-up & Scale-out

Editorial

Critical considerations for allogeneic cell therapy scale up

Research Article

Scale-up of a perfusion-based dendritic cell generation process

Expert Insight

The long road to affordability: a cost of goods analysis for an autologous CAR-T process

Back to the future: where are we taking lentiviral vector manufacturing?

Translating cell and gene therapies to the clinic

Innovator Insight

Commercial Lessons for Clinical Success

Interview

Biopharma scale-up lessons to learn for cell & gene therapy

Towards commercial allogeneic cell therapy manufacturing

Autologous T cell immunotherapy scale out manufacturing models – the biotech perspective

Spotlight

Scale-Out and -Up Strategies

Expert Insight

Scale-up of lentiviral vectors for gene therapy: advances and challenges

Interview

Approaches and challenges for the manufacture and scale-out of autologous cell therapies

Other articles

Research Article

Methylcellulose as a scaffold in the culture of liver-organoids for the potential of treating acute liver failure

Expert Insight

Management of ‘out of specification’ commercial autologous CAR-T cell products

Webinars

Built to scale: strategic considerations to meet production demands in cell and gene therapy

CELL & GENE THERAPY INSIGHTS

Nov 2018. Vol 4 Issue 11

FEATURING

Spotlight

Strategies for Scale-up & Scale-out

Sponsor

Editorial

Critical considerations for allogeneic cell therapy scale up

Research Article

Scale-up of a perfusion-based dendritic cell generation process

Expert Insight

The long road to affordability: a cost of goods analysis for an autologous CAR-T process

Back to the future: where are we taking lentiviral vector manufacturing?

Translating cell and gene therapies to the clinic

Innovator Insight

Commercial Lessons for Clinical Success

Interview

Biopharma scale-up lessons to learn for cell & gene therapy

Towards commercial allogeneic cell therapy manufacturing

Autologous T cell immunotherapy scale out manufacturing models – the biotech perspective

Spotlight

Scale-Out and -Up Strategies

Expert Insight

Scale-up of lentiviral vectors for gene therapy: advances and challenges

Interview

Approaches and challenges for the manufacture and scale-out of autologous cell therapies

Other articles

Research Article

Methylcellulose as a scaffold in the culture of liver-organoids for the potential of treating acute liver failure

Expert Insight

Management of ‘out of specification’ commercial autologous CAR-T cell products

Webinars

Built to scale: strategic considerations to meet production demands in cell and gene therapy